ATA Issues Guidelines for Managing Anaplastic Thyroid Cancer
Evidence - based guidelines address diagnosis, evaluation, and treatment, including early multidisciplinary care team involvement (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - April 16, 2021 Category: Cancer & Oncology Tags: Endocrinology, Oncology, Pathology, Pharmacy, Radiology, Journal, Source Type: news
ATA Issues Guidelines for Managing Anaplastic Thyroid Cancer
FRIDAY, April 16, 2021 -- In new guidelines issued by the American Thyroid Association and published in the March issue of Thyroid, recommendations are presented for the diagnosis, evaluation, and treatment of anaplastic thyroid cancer (ATC).
Keith... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 16, 2021 Category: Pharmaceuticals Source Type: news
Low-Risk Thyroid Cancer: No Benefit of Postsurgical Iodine Low-Risk Thyroid Cancer: No Benefit of Postsurgical Iodine
Forgoing postoperative radioactive iodine in low-risk differentiated thyroid cancer is supported by phase 3 data.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 8, 2021 Category: Cancer & Oncology Tags: Diabetes & Endocrinology News Source Type: news
Outcomes in Lymph Node Metastases of Thyroid Cancer Outcomes in Lymph Node Metastases of Thyroid Cancer
Should active surveillance be considered for thyroid cancer patients with cervical lymph node metastases?Clinical Endocrinology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 2, 2021 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news
Increase in Thyroid Cancer Rates Points to Overscreening Increase in Thyroid Cancer Rates Points to Overscreening
Large but variable increases in rates of papillary thyroid cancer in many countries over the past two decades may point to the"diagnostic pressure" of opportunistic high-sensitivity screening, say experts.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 15, 2021 Category: Cancer & Oncology Tags: Diabetes & Endocrinology News Source Type: news
First lab-grown mini-thyroids use patients' own tissue
(International Society for Stem Cell Research) To investigate potential alternative treatment strategies for patients with hypothyroidism, researchers have now for the first time succeeded in generating thyroid mini-organs in the lab. In a new study published in Stem Cell Reports, Robert Coppes and colleagues from the University of Groningen, The Netherlands, used healthy thyroid tissue from patients undergoing surgical removal of the thyroid to grow mini-thyroid organs in a lab which resembled thyroid glands in their structure and protein content. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 11, 2021 Category: Cancer & Oncology Source Type: news
Could Too Much Light at Night Raise Your Odds for Thyroid Cancer?
(Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - February 10, 2021 Category: Cancer & Oncology Tags: Endocrinology, Oncology, News, Source Type: news
Too Much Light at Night May Raise Odds for Thyroid Cancer
A new study ties an overabundance of nighttime artificial light with an elevated risk of thyroid cancer. (Source: WebMD Health)
Source: WebMD Health - February 10, 2021 Category: Consumer Health News Source Type: news
Could Too Much Light at Night Raise Your Odds for Thyroid Cancer?
WEDNESDAY, Feb. 10, 2021 -- Though living in a bustling urban area may have its upside, all those nighttime lights could come at a price to your health, new research suggests.
The study, published online recently in Cancer, a peer-reviewed journal... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - February 10, 2021 Category: General Medicine Source Type: news
Could Too Much Light at Night Raise Your Odds for Thyroid Cancer?
Title: Could Too Much Light at Night Raise Your Odds for Thyroid Cancer?Category: Health NewsCreated: 2/10/2021 12:00:00 AMLast Editorial Review: 2/10/2021 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - February 10, 2021 Category: Cancer & Oncology Source Type: news
Janssen Announces Treatment with ERLEADA ® (apalutamide) Significantly Improved Overall Survival in Patients with Metastatic Castration-Sensitive Prostate Cancer
RARITAN, N.J., February 8, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today results from the final analysis of the Phase 3 TITAN study, which demonstrated the continued statistically significant benefit of the addition of ERLEADA® (apalutamide) to androgen deprivation therapy (ADT) in overall survival (OS) in patients with metastatic castration-sensitive prostate cancer (mCSPC), regardless of extent of disease, when compared to placebo plus ADT.[1] Results will be featured in an oral presentation at the American Society of Clinical Oncology’s Genitourinary (ASCO GU) Cancers Symposiu...
Source: Johnson and Johnson - February 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Janssen Presents Results from Phase 3 ACIS Study in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with ERLEADA ® (apalutamide) and ZYTIGA® (abiraterone acetate) Combination
RARITAN, N.J., February 8, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today results from the randomized, double-blind, placebo-controlled Phase 3 ACIS study, which met the primary endpoint of radiographic progression-free survival (rPFS) with a 31 percent reduction in the risk of radiographic progression or death in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) receiving androgen deprivation therapy (ADT). Patients in the trial received either a combination of ERLEADA® and ZYTIGA® plus prednisone (combination arm) or placebo and ZYTIGA® pl...
Source: Johnson and Johnson - February 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Artificial Light at Night Tied to Thyroid Cancer Risk
Positive association mainly driven by incidence of papillary thyroid cancer (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - February 8, 2021 Category: Cancer & Oncology Tags: Endocrinology, Oncology, Journal, Source Type: news
Artificial Light at Night Tied to Thyroid Cancer Risk
MONDAY, Feb. 8, 2021 -- Exposure to artificial light at night (LAN) is positively associated with thyroid cancer risk, according to a study published online Feb. 8 in Cancer.
Dong Zhang, Ph.D., from the University of Arkansas for Medical Sciences... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 8, 2021 Category: Pharmaceuticals Source Type: news
Street lamps can increase your risk of thyroid cancer by up to 55%, study shows
Researchers from the University of Texas Health Science Center looked for a link between people developing thyroid cancer and levels of artificial outdoor light. (Source: the Mail online | Health)
Source: the Mail online | Health - February 8, 2021 Category: Consumer Health News Source Type: news
